Table 2.
Point estimates of 10, 20, and 30-year mortality by AYA cancer site and cause of death, diagnosed 1975–2012, SEER-9.
| Primary Cancer Site | n | 10-Year Cumulative Mortality % [95% CI] |
20-Year Cumulative Mortality % [95% CI] |
30-Year Cumulative Mortality % [95% CI] |
|---|---|---|---|---|
| Death due to primary cancer | ||||
| All cancers 1 | 161,207 2 | 5.2 [5.0, 5.3] | 9.6 [9.4, 9.7] | 12.8 [12.5, 13.0] |
| Breast, female | 24,892 | 11.5 [11.1, 11.9] | 21.0 [20.4, 21.6] | 26.4 [25.7, 27.1] |
| Hodgkin lymphoma | 12,581 | 3.4 [3.1, 3.7] | 6.6 [6.1, 7.1] | 10.9 [10.1, 11.7] |
| Non-Hodgkin lymphoma | 8449 | 4.5 [4.0, 5.0] | 9.2 [8.5, 10.0] | 13.7 [12.5, 14.9] |
| Bone/soft tissue sarcoma 1 | 7543 | 6.1 [5.6, 6.7] | 10.0 [9.2, 10.7] | 11.7 [10.9, 12.7] |
| Cervical/uterine | 12,431 | 1.9 [1.6, 2.1] | 3.6 [3.3, 4.0] | 5.4 [4.9, 6.0] |
| Testicular germ cell | 15,210 | 0.4 [0.3, 0.5] | 1.4 [1.2, 1.6] | 2.8 [2.5, 3.3] |
| Melanoma | 22,913 | 3.0 [2.8, 3.2] | 5.8 [5.4, 6.1] | 7.8 [7.4, 8.3] |
| Thyroid | 20,983 | 0.2 [0.1, 0.3] | 0.7 [0.6, 0.9] | 1.6 [1.3, 1.9] |
| Other 1 | 36,205 | 8.0 [7.7, 8.3] | 14.1 [13.7, 14.6] | 18.4 [17.8, 18.9] |
| Death due to subsequent malignancy | ||||
| All cancers 1 | 161,207 2 | 0.2 [0.2, 0.3] | 1.4 [1.3, 1.5] | 4.0 [3.9, 4.2] |
| Breast, female | 24,892 | 0.3 [0.2, 0.4] | 1.8 [1.6, 2.0] | 5.6 [5.1, 6.1] |
| Hodgkin lymphoma | 12,581 | 0.2 [0.2, 0.3] | 2.0 [1.7, 2.3] | 7.0 [6.3, 7.8] |
| Non-Hodgkin lymphoma | 8449 | 0.2 [0.1, 0.4] | 1.3 [1.0, 1.7] | 4.1 [3.3, 5.1] |
| Bone/soft tissue sarcoma 1 | 7543 | 0.4 [0.3, 0.6] | 1.5 [1.2, 1.9] | 3.7 [3.1, 4.5] |
| Cervical/uterine | 12,431 | 0.3 [0.2, 0.5] | 1.5 [1.3, 1.8] | 4.0 [3.5, 4.6] |
| Testicular germ cell | 15,210 | 0.1 [0.1, 0.2] | 1.0 [0.8, 1.2] | 3.6 [3.1, 4.2] |
| Melanoma | 22,913 | 0.1 [0.1, 0.2] | 0.9 [0.7, 1.0] | 2.4 [2.1, 2.7] |
| Thyroid | 20,983 | 0.2 [0.2, 0.3] | 0.9 [0.8, 1.1] | 2.5 [2.1, 2.9] |
| Other 1 | 36,205 | 0.3 [0.3, 0.4] | 1.6 [1.4, 1.8] | 4.2 [3.8, 4.6] |
| Death due to non-malignant causes | ||||
| All cancers 1 | 161,207 2 | 1.1 [1.0, 1.1] | 4.0 [3.9, 4.1] | 9.1 [8.9, 9.4] |
| Breast, female | 24,892 | 0.8 [0.6, 0.9] | 3.0 [2.8, 3.3] | 7.4 [6.8, 8.0] |
| Hodgkin lymphoma | 12,581 | 1.5 [1.3, 1.8] | 6.1 [5.6, 6.6] | 15.9 [14.9, 17.0] |
| Non-Hodgkin lymphoma | 8449 | 1.6 [1.4, 2.0] | 5.7 [5.1, 6.4] | 11.7 [10.5, 13.0] |
| Bone/soft tissue sarcoma 1 | 7543 | 1.1 [0.9, 1.4] | 3.6 [3.1, 4.1] | 7.7 [6.8, 8.6] |
| Cervical/uterine | 12,431 | 1.0 [0.8, 1.2] | 4.3 [3.9, 4.8] | 10.7 [9.9, 11.5] |
| Testicular germ cell | 15,210 | 0.9 [0.7, 1.0] | 3.7 [3.4, 4.1] | 8.9 [8.2, 9.7] |
| Melanoma | 22,913 | 0.5 [0.4, 0.6] | 1.8 [1.6, 2.0] | 4.1 [3.7, 4.5] |
| Thyroid | 20,983 | 0.5 [0.4, 0.6] | 1.9 [1.7, 2.2] | 4.4 [3.9, 4.9] |
| Other 1 | 36,205 | 1.8 [1.6, 1.9] | 6.2 [5.9, 6.5] | 13.0 [12.5, 13.7] |
1 Excluding Kaposi sarcoma; 2 Not included in cumulative mortality analysis = 1100 (1099 with cause of death not available, and 11 prostate cases with stage not recorded); AYA = adolescent and young adult; 95% CI = 95% confidence interval.